Document is current
Any future updates will be listed below
-
Authors
Chakraborty, Rajshekhar https://orcid.org/0000-0001-7336-3003
Cheruvalath, Heloise
Patwari, Anannya
Szabo, Aniko https://orcid.org/0000-0002-8129-0614
Schinke, Carolina https://orcid.org/0000-0002-2699-1741
Dhakal, Binod https://orcid.org/0000-0002-4377-9742
Lentzsch, Suzanne
D’Souza, Anita
Mohyuddin, Ghulam Rehman https://orcid.org/0000-0001-6464-783X
Julian, Kelley
Midha, Shonali
Costello, Patrick
Kaiser, Martin https://orcid.org/0000-0002-3677-4804
Hing, Melissa Ng Liet
Harrison, Simon J. https://orcid.org/0000-0003-4555-6582
Cliff, Edward R. Scheffer https://orcid.org/0000-0001-5977-907X
Mohan, Meera
- License Information
-
More Information
Article History
Received: 23 April 2024
Revised: 27 June 2024
Accepted: 26 July 2024
First Online: 12 August 2024
Competing interests
: RC: Consulting/Advisory Board-Janssen, Sanofi, Adaptive Biotech. SL: Consultant and/or Advisor for Adaptive Biotechnologies, Alexion Therapeutics, Bristol-Meyers-Squibb, Caelum Biosciences, Janssen Pharmaceuticals, Karyopharm Therapeutics, Oncopeptides AB, GSK, Abbvie, Janssen, Pfizer, and Takeda Pharmaceutical Company; receives research funding from Celgene, Inc., Sanofi, Zentalis; received honoraria from Clinical Care Options and Regeneron Pharmaceuticals; and has Royalties/Patents with Caelum Biosciences. In addition, SL has a patent CAEL-101 with royalties paid to Columbia University. AD: Institutional research funding from AbbVie, Caelum, Janssen, Novartis, Prothena, Sanofi, Takeda, and TeneoBio; advisory board fees from BMS, Pfizer, and Janssen; and consulting fees from Prothena and Janssen. BD: Consultant-BMS, Genentech, Janssen, Karyopharm, Natera, Pfozer. SH: Consultant-Celgene, Genentech, Janssen, Novartis. MK: Honoraria: Janssen, Takeda, AbbVie, and Sanofi; consulting or advisory role: AbbVie, GSK, Janssen, Pfizer, Seattle Genetics, Takeda, Adaptive and Poolbeg Pharma. Research funding: BMS/Celgene (to institution) and Janssen (to institution). MM: Institutional Research Funding: Sanofi S.A, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Ionis Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Sanofi S.A, and Amgen Inc; Consultancy: Sanofi S.A, Bristol-Myers Squibb Company, and Pfizer; Honorarium: Blood Cancer Today, MJH life sciences. The remaining authors declare no relevant financial conflicts of interest.
